menu
    • menu
    [{"orgOrder":0,"company":"Mitokinin","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"MTK-458","moa":"PINK1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mitokinin","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Mitokinin \/ AbbVie","highestDevelopmentStatusID":"5","companyTruncated":"Mitokinin \/ AbbVie"},{"orgOrder":0,"company":"Mitokinin","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"MTK-458","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mitokinin","amount2":0.65000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"Mitokinin \/ Abbvie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Mitokinin \/ Abbvie Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Mitokinin

    Menu

    Mitokinin

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mitokinin

                            U.S.A arrow
                            CPHI Middle east
                            Not Confirmed

                            Mitokinin

                            U.S.A arrow
                            CPHI Middle east
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTK-458

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : AbbVie Inc

                            Deal Size : $654.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline

                            Details : Through the acquisition, AbbVie strengthens its neuroscience pipeline, including Mitokinin's lead compound, MTK-458, a selective PINK1 activator, designed to address mitochondrial dysfunction and potentially first-in-class disease-modifying treatment for...

                            Brand Name : MTK-458

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 05, 2023

                            Lead Product(s) : MTK-458

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : AbbVie Inc

                            Deal Size : $654.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mitokinin

                            U.S.A arrow
                            CPHI Middle east
                            Not Confirmed

                            Mitokinin

                            U.S.A arrow
                            CPHI Middle east
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTK-458

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie

                            Details : Under the terms of the agreement, Mitokinin will receive an upfront payment and will continue developing its PINK1 activator program of MTK-458 through completion of IND enabling studies for Mitokinin's lead compound.

                            Brand Name : MTK-458

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 02, 2021

                            Lead Product(s) : MTK-458

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth